Gastrointestinal involvement in Fabry disease

Abstract

Fabry disease is an X-linked lysosomal storage disorder due to alpha-galactosidase A deficiency. This deficiency results in a progressive accumulation of globotriaosylceramide and related glycosphingolipids, particularly in vascular endothelial cells, renal cells, nerve cells, and cardiomyocytes. Gastrointestinal symptoms are frequent and can be extremely debilitating. It is known that most of the well-characterized gastrointestinal manifestations of Fabry disease are the result of the accumulation of glycosphingolipids, which causes vascular occlusion and malfunction of the peripheral and autonomic nervous system. Although improvement is noted in treating patients with enzyme replacement therapy and migalastat, some continue to experience symptoms after treatment; thus, it remains a significant cause of morbidity, necessitating concurrent adjuvant treatment. Current research is focused on clarifying the underlying dysmotility and further analyzing the correlation between the gut-brain axis, the histologic disease progression, and the clinical symptom presentation.

Keywords

Fabry disease / Fabry gastrointestinal involvement / abdominal pain

References

[1] Desnick R,Eng C.Alpha-galactosidase a deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. pp. 3733-74.

[2] Germain DP.Fabry disease.Orphanet J Rare Dis2010;5:30 PMCID:PMC3009617

[3] Wilcox WR,Hopkin RJ.Fabry RegistryFemales with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.Mol Genet Metab2008;93:112-28

[4] Lenders M.Fabry disease - a multisystemic disease with gastrointestinal manifestations.Gut Microbes2022;14:2027852 PMCID:PMC8803088

[5] Zar-Kessler C,Sims KB,Kuo B.Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis.Therap Adv Gastroenterol2016;9:626-34 PMCID:PMC4913334

[6] Keshav S. Chapter 28 gastrointestinal manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis. 2006. Avaliable from: https://www.ncbi.nlm.nih.gov/books/NBK11570/ [Last accessed on 25 Mar 2024]

[7] Friedman LS,Thistlethwaite JR,Kolodny EH.Jejunal diverticulosis with perforation as a complication of Fabry’s disease.Gastroenterology1984;86:558-63.

[8] Jack CI,Nasmyth DG.Colonic involvement in Fabry’s disease.Postgrad Med J1991;67:584-5 PMCID:PMC2398882

[9] Buda P,Ksiazyk J.Gastrointestinal phenotype of Fabry disease in a patient with pseudoobstruction syndrome.JIMD Rep2012;4:25-8 PMCID:PMC3509874

[10] Politei J,Wallace E.Gastrointestinal involvement in Fabry disease. So important, yet often neglected.Clin Genet2016;89:5-9

[11] Politei J,Schenone AB,Mukdsi J.Chronic intestinal pseudo-obstruction. Did you search for lysosomal storage diseases?.Mol Genet Metab Rep2017;11:8-11 PMCID:PMC5369854

[12] Hilz MJ,Dagna L.Non-specific gastrointestinal features: could it be Fabry disease?.Dig Liver Dis2018;50:429-37

[13] Ramaswami U,Parini R.FOS European InvestigatorsClinical manifestations of Fabry disease in children: data from the Fabry outcome survey.Acta Paediatr2006;95:86-92

[14] Deegan PB,Barba Romero MA,Kampmann C.European FOS InvestigatorsNatural history of Fabry disease in females in the Fabry outcome survey.J Med Genet2006;43:347-52 PMCID:PMC2563231

[15] Laney DA,Atherton AM.Fabry disease in infancy and early childhood: a systematic literature review.Genet Med2015;17:323-30

[16] MacDermot KD,Miners AH.Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.J Med Genet2001;38:750-60 PMCID:PMC1734761

[17] MacDermot KD,Miners AH.Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.J Med Genet2001;38:769-75 PMCID:PMC1734754

[18] Di Toro A,Giuliani L.Pathologic substrate of gastropathy in Anderson-Fabry disease.Orphanet J Rare Dis2020;15:156 PMCID:PMC7310490

[19] Hilz MJ.Evaluation of peripheral and autonomic nerve function in Fabry disease.Acta Paediatr Suppl2002;91:38-42

[20] Masotti M,Dothel G.Altered globotriaosylceramide accumulation and mucosal neuronal fiber density in the colon of the Fabry disease mouse model.Neurogastroenterol Motil2019;31:e13529

[21] O'Brien JS,Veath ML.Lysosomal storage disorders. Diagnosis by ultrastructural examination of skin biopsy specimens.Arch Neurol1975;32:592-9

[22] Sheth KJ,Freeman ME.Gastrointestinal structural and function in Fabry’s disease.Am J Gastroenterol1981;76:246-251

[23] Flynn DM,Boothby CB.Gut lesions in Fabry's disease without a rash.Arch Dis Child1972;47:26-33 PMCID:PMC1648012

[24] Jardine DL,Troughton WD.Small bowel ischaemia in Fabry’s disease.J Gastroenterol Hepatol1994;9:201-4

[25] Argoff CE,Brady RO.Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: response to metoclopramide.Nucl Med Commun1998;19:887-91

[26] Bar N,Kiser K,Zar-Kessler C.Gastrointestinal sensory neuropathy and dysmotility in Fabry disease: presentations and effect on patient’s quality of life.Clin Transl Gastroenterol2023;14:e00633 PMCID:PMC10749702

[27] Bryan A,Burns WA.Small bowel perforation in Fabry's disease.Ann Intern Med1977;86:315-6

[28] Cristi E,Ranalli TV,Giannakakis K.Ileocecal appendix involvement in fabry disease mimicking an acute abdomen.J Gastrointest Dig Syst2014;4:239

[29] Kusama M,Koyanagi Y,Yoshimatsu A.A case report of atypical Fabry’s disease with colon cancer.Nihon Geka Gakkai Zasshi1993;94:755-7

[30] Aguilera-Correa JJ,Martínez-Cuesta MDC.Lyso-Gb3 modulates the gut microbiota and decreases butyrate production.Sci Rep2019;9:12010 PMCID:PMC6700068

[31] Feng Z,Dong S.Association between gut dysbiosis and chronic kidney disease: a narrative review of the literature.J Int Med Res2021;49:3000605211053276 PMCID:PMC8554569

[32] Zhao J,Liu B,Bai M.Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review.Ren Fail2021;43:102-12 PMCID:PMC7808321

[33] Delprete C,Lucarini E.Disruption of the microbiota-gut-brain axis is a defining characteristic of the α-Gal A (-/0) mouse model of Fabry disease.Gut Microbes2023;15:2256045 PMCID:PMC10506438

[34] Marchesoni CL,Pardal AM.Misdiagnosis in Fabry disease.J Pediatr2010;156:828-31

[35] Pensabene L,Nicoletti A,Strisciuglio P.Gastrointestinal symptoms of patients with fabry disease.Gastroenterol Res Pract2016;2016:9712831 PMCID:PMC4736195

[36] Shields AL,Taylor F.FABry disease patient-reported outcome-gastroIntestinal (FABPRO-GI): a new Fabry disease-specific gastrointestinal outcomes instrument.Qual Life Res2021;30:2983-94 PMCID:PMC8481178

[37] Eng CM,Wilcox WR.International Collaborative Fabry Disease Study GroupSafety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry’s disease.N Engl J Med2001;345:9-16

[38] Schiffmann R,Austin HA 3rd.Enzyme replacement therapy in Fabry disease: a randomized controlled trial.JAMA2001;285:2743-9

[39] Dehout F,Treille de Granseigne S,Van Maldergem L.Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease.J Inherit Metab Dis2004;27:499-505

[40] Wraith JE,Guffon N.Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease.J Pediatr2008;152:563-70

[41] Hoffmann B,Mehta A.Fabry Outcome Survey European InvestigatorsGastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy.Clin Gastroenterol Hepatol2007;5:1447-53

[42] Wanner C,Wilcox WR.Global reach of over 20 years of experience in the patient-centered Fabry Registry: advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community.Mol Genet Metab2023;139:107603

[43] Wilcox WR,Martins AM.Improvement of Fabry disease-related gastrointestinal symptoms in a significant proportion of female patients treated with agalsidase beta: data from the Fabry Registry.JIMD Rep2018;38:45-51 PMCID:PMC5874211

[44] Hopkin RJ,Germain DP.Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: a Fabry Registry analysis stratified by phenotype.Mol Genet Metab Rep2020;25:100670 PMCID:PMC7606866

[45] Lenders M,Krämer J.Patients with Fabry disease after enzyme replacement therapy dose reduction and switch-2-year follow-up.J Am Soc Nephrol2016;27:952-62 PMCID:PMC4769208

[46] Germain DP,Giugliani R.Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study.Genet Med2019;21:1987-97 PMCID:PMC6752321

[47] Schiffmann R,Jovanovic A.Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.Orphanet J Rare Dis2018;13:68 PMCID:PMC5923014

[48] Shayman JA,Shu L.Inhibitors of glucosylceramide synthase. In: Kabayama K, Inokuchi J, editors. Glycolipids. New York: Springer; 2023. pp. 271-88.

[49] Wanner C,Politei J.Understanding and modifying Fabry disease: rationale and design of a pivotal phase 3 study and results from a patient-reported outcome validation study.Mol Genet Metab Rep2022;31:100862 PMCID:PMC9248229

[50] Deegan PB,Geberhiwot T.Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study.Mol Genet Metab2023;138:106963 PMCID:PMC9918698

[51] Burlina AP,Politei JM.Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel.BMC Neurol2011;11:61 PMCID:PMC3126707

[52] Ries M,Kutschke G.Use of gabapentin to reduce chronic neuropathic pain in Fabry disease.J Inherit Metab Dis2003;26:413-4

[53] Gugelmo G,Francini-Pesenti F.Gastrointestinal manifestations and low-fodmap protocol in a cohort of Fabry disease adult patients.Nutrients2023;15:658 PMCID:PMC9920936

[54] Lenders M,Auray-Blais C.Effects of orally delivered alpha-galactosidase A on gastrointestinal symptoms in patients with Fabry disease.Gastroenterology2020;159:1602-4

[55] Monticelli M,Allocca M.Curcumin Has beneficial effects on lysosomal alpha-galactosidase: potential implications for the cure of Fabry disease.Int J Mol Sci2023;24:1095 PMCID:PMC9863837

[56] Bertoldi G,Ravarotto V.The effect of green tea as an adjuvant to enzyme replacement therapy on oxidative stress in fabry disease: a pilot study.Front Nutr2022;9:924710 PMCID:PMC9304972